重复细胞学联合反射性ThyroSeq基因组分类器在甲状腺不确定细胞学中的性能
该研究分析24个月内187例初次FNAB为AUS/FLUS并接受重复FNAB的患者,64%重复活检仍为不确定诊断;其中63%的重复结节接受ThyroSeq v3检测,仅手术确诊结节计算灵敏度100%、特异度30%,将未切除且ThyroSeq阴性或细胞学良性视为良性时特异度88%。结论认为该算法增加活检次数并延长明确风险分层时间,未显著减少分子检测使用或改善诊断性能。
要点
- 重复FNAB后多数AUS/FLUS结节仍为不确定诊断,需分子检测辅助分层。
- ThyroSeq v3反射检测在手术确诊结节中灵敏度100%、特异度30%。
- 将未切除且分子/细胞学阴性视为良性时,特异度提高至88%。
核心结论
- 对AUS/FLUS结节重复FNAB后行反射性ThyroSeq检测,诊断性能与单独重复活检或单独分子检测相似。
- 该算法增加活检次数并延长至明确风险分层的时间,未显著减少分子检测使用或改善诊断性能。
研究设计与样本
- 回顾性分析24个月内187例初次FNAB诊断为AUS/FLUS并接受重复FNAB的患者。
主要发现
- 64%患者重复活检仍为不确定诊断:3.7%为非诊断/不满意,55.6%为AUS/FLUS,4.3%为滤泡性肿瘤/可疑滤泡性肿瘤。
- 63%的重复活检结节接受ThyroSeq version 3检测。
- 仅手术确诊结节:灵敏度100%、特异度30%、阳性预测值41%、阴性预测值100%。
- 将未切除且ThyroSeq阴性或细胞学良性视为良性:灵敏度100%、特异度88%、阳性预测值41%、阴性预测值100%。
关键数值与推荐
- 美国甲状腺协会推荐对Bethesda III类(AUS/FLUS)结节行重复FNAB或分子检测(如ThyroSeq)以进一步风险分层。
临床怎么用
- 对AUS/FLUS结节重复FNAB后仍不确定时,可行反射性ThyroSeq检测辅助风险分层。
- 需注意该算法可能增加活检次数并延长明确诊断时间,诊断性能未显著优于单独策略。
局限性
- 回顾性设计,仅纳入接受重复FNAB的患者,部分结节缺乏手术确诊。
- 诊断性能计算中部分未切除结节被假设为良性,可能影响特异度等指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Thyroid Association recommends either repeat fine-needle aspiration biopsy (FNAB) or molecular testing (eg, ThyroSeq) of Bethesda category III (atypia of undetermined significance/follicular lesion of undetermined significance [AUS/FLUS]) nodules to provide further risk stratification. How a testing algorithm that uses ancillary molecular tests performs as a reflex test for repeat sampling of indeterminant nodules remains unclear. METHODS: Thyroid FNABs performed over a 24-month period that received a diagnosis of AUS/FLUS and underwent subsequent FNAB were analyzed. RESULTS: In total, 187 patients were identified who received an FNAB diagnosis of AUS/FLUS and had repeat sampling. Of these patients, 64% received a subsequent indeterminant diagnosis on repeat biopsy: 7 (3.7%) repeat biopsies were diagnosed as nondiagnostic/unsatisfactory, 104 (55.6%) were diagnosed as AUS/FLUS, and 8 (4.3%) were diagnosed as follicular neoplasm/suspicious for follicular neoplasm. Of the repeat biopsied nodules, 63% underwent subsequent testing with ThyroSeq version 3. The diagnostic performance was calculated using only surgically confirmed nodules (sensitivity, 100%; specificity, 30%; positive predictive value, 41%; negative predictive value, 100%) and by assigning nonresected nodules with negative ThyroSeq or benign cytology results as benign (sensitivity, 100%; specificity, 88%; positive predictive value, 41%; negative predictive value, 100%). CONCLUSIONS: In the majority of patients, repeat FNAB for AUS/FLUS did not preclude subsequent molecular ancillary testing because of the high rate of indeterminant results on repeat biopsy. The diagnostic performance of the testing algorithm reported here was very similar to other reports using either repeat biopsy or molecular testing alone. Ultimately, the algorithm of performing molecular testing on repeat indeterminant nodules increased the number of biopsies performed and lengthened the time to definitive risk stratification without a disproportionate decrease in the use of molecular testing or an appreciable improvement in diagnostic performance.
引用
- O'Conor CJ, Dash RC, Jones CK, et al. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology. Cancer Cytopathol. 2022. PMID: 35045202. doi:10.1002/cncy.22552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。